 |
26 Diseases |  |
6 Trials |
|
6 Trials |  |
4342 News |  |
| «12...2627282930313233343536...5051» |
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Cardiovascular Benefits of #Vascepa Greater for Those With Diabetes, New REDUCE-IT Data Show @DLBHATTMD https://t.co/IEK6Th8jw1 (Twitter) - Jun 13, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: REDUCE-IT DIABETES Strengthens Icosapent Ethyl's Safety, Efficacy Profile https://t.co/8HyzhYITxZ via @mdmagazine #diabetes #Cardiology #cardiotwitter #ADA2020 #ADAGoesVirtual (Twitter) - Jun 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Cardiovascular Benefits of Vascepa Greater for Those With Diabetes, New REDUCE-IT Data Show https://t.co/NgLle3Iur5 via @AJMC_Journal #diabetes #ADA2020 (Twitter) - Jun 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Why are you not using “Vascepa” in any of these recent tweets? (Twitter) - Jun 13, 2020
- ||||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Research by @DLBHATTMD at the @AmDiabetesAssn Scientific Sessions shows 4g/day of icosapent ethyl provides #CV benefits in statin-treated patients with #diabetes with risk reductions in both first and total CV events. #Amarin #ADAGoesVirtual #ADA2020 #ADA #statins #hearthealth (Twitter) - Jun 13, 2020
- ||||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Day two of @AmDiabetesAssn Scientific Sessions as @DLBHATTMD discusses the #CV benefits of icosapent ethyl in statin-treated patients with #diabetes. #Amarin #ADAGoesVirtual #ADA2020 #statins #ADA #hearthealth (Twitter) - Jun 13, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Oh boy, I can’t stop eating. Spent hours working up some latkes, the old fashioned way but cooked em in vascepa oil. Food coma now! (Twitter) - Jun 12, 2020
- ||||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Today the 80th Scientific Sessions presented by @AmDiabetesAssn begins! On Saturday @DLBHATTMD presents an analysis of the potential #CV benefit of icosapent ethyl on statin-treated patients with #diabetes. #Amarin #ADA2020 #ADAGoesVirtual #ADA #statins #hearthealth (Twitter) - Jun 12, 2020
- ||||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Today the 80th Scientific Sessions presented by @AmDiabetesAssn begins! On Sunday @DLBHATTMD presents an analysis of the potential #CV benefit of icosapent ethyl on statin-treated patients with #diabetes. #Amarin #ADA2020 #ADAGoesVirtual #ADA #statins #hearthealth (Twitter) - Jun 12, 2020
- | icosapent ethyl / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: PREPARE: PRevention Using EPA Against coloREctal Cancer (clinicaltrials.gov) - Jun 11, 2020
P1/2, N=80, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Dec 2020 --> Aug 2021
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
@DLBHATTMD Hello Dr. Bhatt. From REDUCE-IT data, has Vascepa shown reduction in hypertension due to its ability to reduce inflammation in arteries and high levels in blood serum? (Twitter) - Jun 10, 2020
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] VASCEPA® (icosapent ethyl)—Elevating the Standard of Care (Product Theater #2) - Jun 10, 2020 - Abstract #ADA2020ADA_3737;
There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statinbased standard-of-care therapy in patients with elevated triglycerides. In this program, we will reviewdata from a practice changing trial that provides a new therapeutic option to elevate the currentstandard of care.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Well, unless the court ruling denying Vascepa patent protection is overruled (unlikely) there are cheap generics coming soon. But don't expect anyone else to blow $100m's developing something new that a single judge can deny them patent protection for. (Twitter) - Jun 9, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Research into Vascepa would cease prematurely, a gentle reminder to everyone that cardiovascular studies typically require long timeframes and large patient populations. Generic companies perform no such studies. (Twitter) - Jun 9, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Got to present REDUCE-IT trial from @DLBHATTMD and colleagues on rounds and discuss residual risk in the context of a statin-treated patient with hypertriglyceridemia. Now, if only we could make meds like Vascepa more accessible to our underserved and uninsured patients... (Twitter) - Jun 9, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: If Mori et al is to be disregarded in patent caae because of flawed statistical concerns, then studies comparing icosapent ethyl to mineral oil should also be disregarded in patent case due to flawed placebo concern. (Twitter) - Jun 9, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Truth matters. Right versus wrong matters. Vascepa has a strong clinical benefit. $AMRN should have exclusivity by funding the trial. Having an opinion that Du f..k up is valid, imo. Your “journalism” has proven to be slanted re AMRN. (Twitter) - Jun 9, 2020
- ||| Lypdiso (omega-3 pentaenoic acid) / Matinas
Enrollment open, Trial completion date: ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - Jun 9, 2020
P2, N=100, Recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
In this program, we will reviewdata from a practice changing trial that provides a new therapeutic option to elevate the currentstandard of care. Not yet recruiting --> Recruiting | Trial completion date: Nov 2020 --> Feb 2021
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
It amazes me that a medical journalist @adamfeuerstein has to ask why Judge Du’s ruling and a generic introduced this early into Vascepa’s lifespan is a negative. Considering our system, how is it a good thing? Luckily no one views you as a “journalist,” rather a paid troll. (Twitter) - Jun 8, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Adam- REDUCE-IT study deserves full marketing campaign due to valid IP; if you don‘t get this concept then you have learned nothing over the years you’ve covered biotech. The medical purpose it serves is further build out of icosapent ethyl studies. (Twitter) - Jun 8, 2020
- ||||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: June 12th marks @AmDiabetesAssn 80th Scientific Sessions. We are excited to announce @DLBHATTMD will be discussing the #CV benefits of icosapent ethyl on statin-treated patients with #diabetes. #Amarin #ADAGoesVirtual #ADA2020 #ADA #statins #hearthealth @ADA_DiabetesPro (Twitter) - Jun 8, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Have you seen this ?? @MarkmanAdvisors: We received several inquiries regarding Dr. Bhatt's very interesting article. See our thoughts in the comment section to our prior post on Amarin's opening brief, linked below. $AMRN #vascepa https://t.co/j9aiFRd55n (Twitter) - Jun 6, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Thank you. I am a not a religious person but you, Dr. Bhatt are doing God's work. After this ruling is overturned, your work (this paper & Reduce-it & continuous education about Vascepa) will result in a saving of thousands of lives to CVD. $AMRN (Twitter) - Jun 6, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
So we can all agree that svg grafting is better than asa. But both options have changed dramatically. Is it really unequivocal that arterial grafting is better than high potency statin, pcsk9 and vascepa? (Twitter) - Jun 6, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Let's not forgot the residual ASCVD risk even after LDL lowering. I would check triglycerides and consider icosapent ethyl. No need to reduce or withdraw his LDL meds (if $$ isn't an issue). #reduceit @DLBHATTMD (Twitter) - Jun 6, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Thanks for the Abstract @DLBHATTMD - Let´s see, if the federal circuit brings justice back to @Amarincorp and their product - Vascepa :) (Twitter) - Jun 6, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Thank you for your hard work and contributions to bring Vascepa and the Reduce It study to patients who need it! (Twitter) - Jun 5, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
$AMRN RT @DLBHATTMD: Federal Judge Invalidates Icosapent Ethyl Patents – But Based on a Common Statistical Mistake @SSRN https://t.co/YF3FbmJFjE #cardiology #cardiotwitter (Twitter) - Jun 5, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Federal Judge Invalidates Icosapent Ethyl Patents – But Based on a Common Statistical Mistake @SSRN https://t.co/t3iNf2RTo5 #cardiology #cardiotwitter (Twitter) - Jun 5, 2020
- | icosapent ethyl / Generic mfg.
Biomarker, Enrollment open: An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (clinicaltrials.gov) - Jun 5, 2020
P2, N=100, Recruiting, Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
Not yet recruiting --> Recruiting | Trial completion date: Nov 2020 --> Feb 2021 Not yet recruiting --> Recruiting
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Now we have icosapent ethyl. #om3 #cvlipids (Twitter) - Jun 4, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
@DLBHATTMD Any reason why you chose only 14 days for the trial when in R-it you see the benefits of Vascepa increase with time? Also, why so long with a December completion date? https://t.co/Y8zSgsPlVW (Twitter) - Jun 2, 2020
- | icosapent ethyl / Generic mfg.
Biomarker, New P2 trial: An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (clinicaltrials.gov) - Jun 2, 2020
P2, N=100, Not yet recruiting, Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
@SmithDanaG I'm not sure if you are aware of it but the only drug proven to reduce cardiovascular risk, protects endothelial cells & reduces heart attacks & clots is an approved drug called Vascepa. It may be the best #COVID19 weapon yet. @DLBHATTMD $amrn (Twitter) - Jun 1, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Following immediately after icosapent ethyl! Congrats. Do you think that baseline EPA levels being higher in East Asia, that could explain better endothelial integrity without leaks that would infect pericytes and cause microvascular inflammation? (Twitter) - Jun 1, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
$AMRN Plans to Increase VASCEPA Promotion and Education. https://t.co/wnERRegYce (Twitter) - Jun 1, 2020
- | Review, Journal: What's new in lipid lowering therapies in diabetes? (Pubmed Central) - May 31, 2020
Finally, this review will touch on agents still on the horizon such as icosapent ethyl, high-density lipoprotein (HDL) mimetics, bempedoic acid, omega-3 free fatty acids, bromodomain and extra-terminal proteins (BET) inhibitors and inclisirin - a long-acting RNA interference agent. In the appropriately selected population of individuals with diabetes, these agents can assist to further improve lipid profile and reduce cardiovascular events.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
@DLBHATTMD @Amarincorp Important information for you guys. Icosapent Ethyl protects blood vessels. $gsx $tsla #minneapolisriots #ChinaIndiaFaceoff #Twitter #TwitterPicksSides #TwitterFactCheck https://t.co/oPl1NjppDP (Twitter) - May 29, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Wouldn’t it be great if Dr Bhatt could do the @60Minutes piece, then receive @NobelPrize followed by a Board seat or new ceo of $amrn? Now that would be the paradigm shift #Vascepa needs @Amarincorp (Twitter) - May 28, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: It’s time to start thinking more seriously about starting at-risk patients with elevated triglycerides on icosapent ethyl. These large reductions in revasc could play an important role in the residual risk conundrum. @DLBHATTMD @webmd11 @BrighamFellows https://t.co/Cm0ePFw6oY (Twitter) - May 27, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial - American College of Cardiology https://t.co/MgYuj4YUut #cardiology #cardiotwitter (Twitter) - May 27, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Dr. @benpeterson71 slipping in a very nice presentation between cases in the cath lab: Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia https://t.co/8Eqk9ici1b #cardiology #cardiotwitter #SCAI2020 @SCAI @BrighamFellows (Twitter) - May 27, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
FDA event, P4 data: What i can't believe is fda did not ask for such a DDI study before approving reduceIT indication for vascepa ? They could have at least demanded a post-marketing study. (Twitter) - May 23, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
FDA event: FDA needed trials which took years and millions of dollars to prove Vascepa actually works . But FDA granted approval to generics in 2 months based on a judgement which invalidated US patent office’s work . @DLBHATTMD @Amarincorp $amrn (Twitter) - May 22, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
FDA event, Generic launch: FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?https://t.co/BED0FFy6d6 (Twitter) - May 22, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
FDA event: $HKMPY Hikma receives FDA approval for generic of $AMRN's Vascepa. https://t.co/0cOHjh0FuW $AMRN (Twitter) - May 22, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
And Judge Du's $amrn ruling cripples important paths to fund testing and distribution. Let's ghost write her next opinion: "Vascepa's effect on COVID-19 of doing _____ was totally obvious". Just fill in the blank after we get study results. (Twitter) - May 21, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
$AMRN #icosapentethyl #IPE @DLBHATTMD's association with the study certainly lends credibility to the effort. (Twitter) - May 21, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Nice to see Amarin providing support for this study as well as Dr. Bhatt's involvement. Hopeful that icosapent ethyl can help prevent some of these strokes that they're seeing. https://t.co/jPTIZqqyKS (Twitter) - May 21, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Journal: Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. (Pubmed Central) - May 21, 2020
In the appropriately selected population of individuals with diabetes, these agents can assist to further improve lipid profile and reduce cardiovascular events. No abstract available